title: Changes in labelling for metformin use in patients with type 2 diabetes and heart failure: documented safety outweighs theoretical risks.
authors: Department of Public Health Sciences, School of Public Health 2-040 HRIF East, University of Alberta, Edmonton. AB T6G 2E1. deurich@ualberta.ca
authors: Dean T
authors: DT
authors: Eurich
authors: Sumit R
authors: SR
authors: Majumdar
authors: Finlay A
authors: FA
authors: McAlister
authors: Ross T
authors: RT
authors: Tsuyuki
authors: Jeffrey A
authors: JA
authors: Johnson
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000473:pathology; D004348:Drug Labeling / Q000379:methods*; D064420:Drug-Related Side Effects and Adverse Reactions; D006333:Heart Failure / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment / Q000379:methods*
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin